A phase Ib multicenter study aimed to investigate the effects of buparlisib (BKM120, NVP-BKM120, Selleck Chemicals), a pan-PI3K inhibitor in patients with solid tumors (triple-negative breast cancer, ovarian, cutaneous melanoma, colorectal cancer, non-small cells lung cancer), including in subjects with pancreatic cancer [168]. Here, PIK3CD is linked to pancreatic neoplasm.